Study guide
2.4 Risk Factors, Secondary Causes, and Bone-Compromising Medications
ARRT Bone Densitometry Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Orientation & the ARRT Blueprint
1.1 About the ARRT Bone Densitometry Examination 1.2 Eligibility, Structured Education, and Clinical Experience
2 Chapter 2: Osteoporosis, Bone Biology & Risk Factors
2.1 Osteoporosis: Definitions, Types, and WHO Diagnostic Criteria 2.2 Bone Functions, Structural Anatomy, and Bone Types 2.3 Bone Cells, the Remodeling Cycle, and Calcium Homeostasis 2.4 Risk Factors, Secondary Causes, and Bone-Compromising Medications
3 Chapter 3: Indications, Prevention & Treatment
3.1 The Bone Mass Measurement Act: Covered Indications and Coding 3.2 Prevention: Nutrition, Exercise, Smoking Cessation, and Fall Prevention 3.3 Osteoporosis Drug Therapy: Antiresorptive, Anabolic, and Hormonal Agents
4 Chapter 4: Patient Preparation, Support & Radiation Safety
4.1 Patient Support, Disabilities, Ergonomics, and Transfer Techniques 4.2 Patient Instructions: Explaining the Exam, Dose, Duration, and Motion Control 4.3 Patient History, Contraindications, and Pregnancy Screening 4.4 Scan Preparation: Patient Data Entry, Artifact Removal, and Infection Control 4.5 Radiation Safety in DXA: ALARA, Distance, and Dose Levels
5 Chapter 5: DXA Physics & Instrumentation
5.1 Physical Principles of Dual-Energy X-ray Absorptiometry 5.2 Beam Geometries: Pencil Beam and Fan Beam Systems 5.3 Fan-Beam Geometry: Source–Object–Detector Distances, Magnification, and Centering 5.4 The Scan Analysis Algorithm: Soft Tissue, Bone Edge Detection, BMC, Area, and BMD
6 Chapter 6: Measuring & Reporting Bone Mineral Density
6.1 Statistics for Densitometry: Mean, Standard Deviation, and Coefficient of Variation 6.2 T-Scores, Z-Scores, and Reference Database Selection 6.3 Clinical Indications for BMD Testing and the FRAX Tool 6.4 Vertebral Fracture Assessment and Trabecular Bone Score 6.5 Whole Body DXA, Body Composition, and Pediatric Scanning
7 Chapter 7: Quality Control, Precision & Equipment Management
7.1 Accuracy, Precision, and the Sources of Precision Error 7.2 Daily Quality Control, Phantoms, and Control Charts 7.3 In Vivo Precision Studies and RMS-SD Calculation 7.4 Determining and Applying the Least Significant Change 7.5 Maintenance, Repair, Relocation, Cross-Calibration, and Software Upgrades
8 Chapter 8: DXA Informatics & Data Management
8.1 DXA Informatics, DICOM, PACS, and Data Management
9 Chapter 9: Lumbar Spine DXA
9.1 Lumbar Spine Anatomy, Landmarks, and Regions of Interest 9.2 Lumbar Spine Scan Acquisition and ROI Edge Placement 9.3 Lumbar Spine: Compensating for Body Habitus, Variant Anatomy, Pathology, and Low Bone Density 9.4 Lumbar Spine Positioning: The Leg Block, Centering, and Common Challenges 9.5 Lumbar Spine Problems: Poor Bone Edge Detection and Obscured Intervertebral Spaces 9.6 Lumbar Spine: Variant Anatomy, Fractures, Degenerative Pathology, Calcification, and Surgery 9.7 Lumbar Spine Analysis: Vertebral Exclusion and Reporting Rules 9.8 Lumbar Spine Follow-Up Scans and Rate of Change
10 Chapter 10: Proximal Femur DXA
10.1 Proximal Femur Anatomy, Landmarks, and Regions of Interest 10.2 Femur Selection: Right, Left, and Dual Femur Scanning 10.3 Proximal Femur Scan Parameters and Compensation 10.4 Proximal Femur Positioning: Neck Rotation, Shaft Placement, and Positioning Aids 10.5 Proximal Femur Problems: Ischium, Short Neck, Arthritis, Fracture, and Hardware 10.6 Femoral ROI Analysis: Femoral Neck, Total Hip, and Ward's Area 10.7 Proximal Femur Follow-Up Scans and Rate of Change
11 Chapter 11: Forearm DXA
11.1 Forearm Anatomy, Landmarks, and Adjacent Structures 11.2 Forearm Indications and Side Selection 11.3 Forearm Length Measurement, Scan Parameters, and Positioning 11.4 Forearm Regions of Interest: One-Third, Mid, Ultradistal, and Total 11.5 Forearm Problems: Edge Detection, Artifacts, Low Bone Density, and Joint Disease 11.6 Scan Analysis: Region Placement, Window Level, and Reported Values 11.7 Forearm Follow-Up Scans and Rate of Change
12 Chapter 12: Cross-Site Artifacts & Clinical Integration
12.1 Recognition, Impact, and Management of DXA Artifacts 12.2 Clinical Interpretation, Serial Comparison, and Reporting
2.4 Risk Factors, Secondary Causes, and Bone-Compromising Medications
Key Takeaways Explain This Topic AI
Non-modifiable fracture risk factors include advanced age (the strongest independent predictor), female sex, Caucasian/Asian ethnicity, low BMI (< 19 kg/m²), personal history of adult fragility fracture, and parental history of hip fracture.
Modifiable risk factors encompass tobacco smoking (accelerates hepatic estrogen metabolism and exerts direct osteoblast toxicity), heavy alcohol use (>= 3 units/day), sedentary lifestyle, and inadequate calcium/vitamin D intake.
Secondary osteoporosis affects up to 30% of postmenopausal women and >50% of men, driven by endocrine disorders (hyperparathyroidism, Cushing's, hyperthyroidism), malabsorption (celiac disease, Roux-en-Y gastric bypass), and hematologic malignancies (multiple myeloma).
Systemic glucocorticoid therapy (prednisone >= 5 mg/day for >= 3 months) is the most common cause of secondary drug-induced osteoporosis, triggering rapid trabecular bone loss and fracture risk at higher BMD T-scores.
Other key bone-demineralizing medications include enzyme-inducing anticonvulsants (accelerating CYP3A4-mediated vitamin D clearance), aromatase inhibitors (inducing complete estrogen depletion), androgen deprivation therapy, and chronic proton pump inhibitors.
Last updated: September 2026
2.4 Risk Factors, Secondary Causes, and Bone-Compromising Medications
Quick Answer: Clinical fracture risk assessment integrates non-modifiable factors (advanced age, female sex, Caucasian/Asian descent, BMI < 19 kg/m², prior adult fragility fracture, and parental hip fracture) with modifiable risks (cigarette smoking, excessive alcohol ≥ 3 \ge 3 ≥ 3 units/day, sedentary lifestyle, and calcium/vitamin D deficits). Secondary osteoporosis occurs in up to 30% of postmenopausal women and >50% of men, driven by endocrine disorders (hyperparathyroidism, Cushing's, hyperthyroidism, hypogonadism), gastrointestinal malabsorption (celiac disease, bariatric bypass, IBD), and hematologic malignancies (multiple myeloma). Systemic glucocorticoids (prednisone ≥ 5 \ge 5 ≥ 5 mg/day for ≥ 3 \ge 3 ≥ 3 months) represent the leading drug-induced cause of bone loss, followed by enzyme-inducing anticonvulsants, aromatase inhibitors, androgen deprivation therapy, and chronic proton pump inhibitors.
Clinical Risk Factors: Non-Modifiable vs. Modifiable
Comprehensive fracture risk evaluation requires combining DXA bone mineral density with independent clinical risk factors that compromise bone quality or elevate fall propensity:
Non-Modifiable Risk Factors
Advanced Age: The single most powerful independent predictor of fracture. Age-related fracture risk increases exponentially due to microarchitectural decay, cortical thinning, increased intracortical porosity, declining neuromuscular reflexes, and higher fall incidence.
Female Sex: Women possess a lower peak bone mass, smaller bone geometry, and undergo accelerated bone loss following menopause due to estrogen withdrawal, sustaining roughly 70% of all fragility fractures.
Race / Ethnicity: Caucasian and Asian populations exhibit the highest incidence of osteoporosis and fractures. Hispanic individuals show intermediate risk. African American individuals generally possess thicker cortices, greater trabecular volume, and higher peak BMD; however, post-fracture mortality is disproportionately high.
Low Body Habitus / Slender Frame: Low body weight (< 127 lbs or 57.7 kg) or low body mass index (BMI < 19 kg/m 2 \text{kg/m}^2 kg/m 2 ). Slender individuals experience reduced mechanical skeletal loading (lower strain-mediated osteogenesis via Wolff's law) and possess less adipose tissue, limiting peripheral aromatase conversion of adrenal androgens into estrogens.
Personal History of Adult Fragility Fracture: Having sustained a low-trauma fracture in adulthood doubles to quadruples future fracture risk. This imminent fracture risk is highest within the initial 12 to 24 months post-fracture.
Parental History of Hip Fracture: Maternal or paternal hip fracture carries a strong hereditary predisposition independent of BMD, serving as a key input in the FRAX assessment tool.
Modifiable Risk Factors
Cigarette Smoking: Exerts multifactorial adverse effects: nicotine is directly cytotoxic to osteoblasts; smoking induces hepatic CYP450 enzymes that accelerate estrogen metabolism; induces earlier natural menopause by 1 to 2 years; reduces intestinal calcium absorption; and associates with lower body weight.
Excessive Alcohol Consumption: Intake of 3 or more units of alcohol daily (e.g., >2 standard drinks/day) directly blunts osteoblast proliferation and matrix synthesis, triggers hypercortisolemia, impairs hepatic 25-hydroxylation of vitamin D, causes malnutrition, and markedly elevates fall risk through intoxication and cerebellar ataxia.
Physical Inactivity / Sedentary Lifestyle: Prolonged immobilization or lack of weight-bearing and resistance exercise eliminates skeletal strain. In the absence of mechanical strain, osteocytes increase sclerostin production, arresting osteoblast Wnt signaling and promoting osteoclastic resorption (disuse osteopenia).
Inadequate Calcium and Vitamin D Intake: Dietary calcium below 1000–1200 mg/day or vitamin D intake below 800–1000 IU/day (serum 25 ( OH ) D < 20 25(\text{OH})\text{D} < 20 25 ( OH ) D < 20 –30 ng/mL) triggers persistent secondary hyperparathyroidism, which mobilizes skeletal calcium stores to defend serum levels. Excessive caffeine and high sodium intake exacerbate renal hypercalciuria.
Secondary Causes of Osteoporosis: Systemic Etiologies
Secondary osteoporosis accounts for bone loss in up to 30% of postmenopausal women and over 50% of men. Underlying disorders should be investigated whenever bone loss is severe or disproportionate to age:
Organ System Disease Condition Pathophysiological Mechanism Characteristic Skeletal / DXA Pattern
Endocrine Primary Hyperparathyroidism Autonomous PTH secretion drives high-turnover cortical resorption Preferential cortical bone loss; prominent deficit at 33% radius
Endocrine Cushing's Syndrome Chronic cortisol excess suppresses osteoblasts & induces apoptosis Marked trabecular loss (lumbar spine); rib and vertebral fractures
Endocrine Hyperthyroidism Excess T3/T4 accelerates bone turnover, shortening cycle length Generalized high-turnover bone loss across spine and hips
Endocrine Hypogonadism Sex steroid deficiency removes inhibition of RANKL Rapid high-turnover trabecular loss mirroring early menopause
Gastrointestinal Celiac Disease Autoimmune villous atrophy causes calcium & vitamin D malabsorption Low BMD accompanied by elevated PTH and low 25(OH)D
Gastrointestinal Bariatric Bypass (Roux-en-Y) Duodenal bypass eliminates active transcellular calcium uptake Rapid secondary hyperparathyroidism and hip bone loss
Gastrointestinal Inflammatory Bowel Disease Systemic cytokine release (TNF-α) plus steroid-induced bone loss Combined cortical and trabecular demineralization
Hematologic Multiple Myeloma Malignant plasma cells produce MIP-1α & DKK1, driving osteolysis Diffuse severe osteopenia, lytic bone lesions, normal ALP
Rheumatologic Rheumatoid Arthritis Systemic inflammatory cytokines stimulate osteoclastogenesis Periarticular and axial bone loss; elevated fracture risk
Renal Chronic Kidney Disease (CKD) Calcitriol deficiency and phosphate retention drive hyperparathyroidism Mixed renal osteodystrophy, vascular calcification, fracture risk
Bone-Active Medications
Pharmacological agents represent a major category of secondary bone loss:
Glucocorticoids (The #1 Cause of Secondary Osteoporosis)
Systemic administration of oral prednisone ≥ 5 \ge 5 ≥ 5 mg/day (or equivalent) for 3 consecutive months or longer is the leading cause of drug-induced osteoporosis.
Mechanisms: Directly inhibits osteoblast differentiation (suppressing Runx2) and collagen synthesis, while accelerating osteoblast and osteocyte apoptosis; inhibits active intestinal calcium absorption (antagonizing calcitriol) and promotes renal hypercalciuria; suppresses pituitary gonadotropins.
Clinical Presentation: Fractures occur at higher BMD T-scores (e.g., -1.5 to -2.0) compared to primary osteoporosis. Bone loss is rapid, with up to 10% to 15% loss occurring within the first 3 to 6 months of therapy, predominantly depleting trabecular bone in the spine and ribs.
Other High-Yield Bone-Active Medications
Anticonvulsants (CYP450 Enzyme Inducers): Phenytoin, carbamazepine, and phenobarbital induce hepatic CYP3A4, accelerating catabolism of 25(OH)D and 1 , 25 ( OH ) 2 D 1,25(\text{OH})_2\text{D} 1 , 25 ( OH ) 2 D into inactive metabolites (calcitroic acid), causing hypocalcemia, secondary hyperparathyroidism, osteomalacia, and bone loss.
Aromatase Inhibitors (AIs): Anastrozole, letrozole, and exemestane inhibit peripheral aromatase conversion of androgens to estrogens, causing near-total estrogen depletion and rapid bone loss (2%–4% annually at spine and hip).
Androgen Deprivation Therapy (ADT): GnRH agonists (leuprolide) and antagonists (degarelix) ablate testosterone and estrogen simultaneously in men with prostate cancer, triggering rapid demineralization.
Proton Pump Inhibitors (PPIs): Chronic omeprazole or pantoprazole elevates gastric pH. Hypochlorhydria impairs dissolution of insoluble calcium carbonate; water-soluble calcium citrate is preferred.
SSRIs, Heparin, and DMPA: SSRIs antagonize osteoblast serotonin receptors; prolonged unfractionated heparin stimulates resorption; and depot medroxyprogesterone (DMPA) suppresses gonadotropins, causing reversible bone loss.
Medication Class Common Agents Primary Mechanism of Bone Loss Management / Clinical Strategy
Glucocorticoids Prednisone, dexamethasone Osteoblast/osteocyte apoptosis, decreased Ca²⁺ absorption Fracture risk elevated at higher T-scores; early bisphosphonate prophylaxis
Anticonvulsants Phenytoin, carbamazepine Induces CYP3A4; accelerates vitamin D catabolism Monitor 25(OH)D levels; high-dose vitamin D and calcium repletion
Aromatase Inhibitors Anastrozole, letrozole Complete ablation of peripheral estrogen synthesis Baseline DXA scan; antiresorptive therapy if T-score < -2.0
Androgen Deprivation Leuprolide, degarelix Profound suppression of testosterone and secondary estradiol Baseline DXA; lifestyle optimization and antiresorptive therapy
Proton Pump Inhibitors Omeprazole, pantoprazole Hypochlorhydria prevents ionization of calcium carbonate Switch to calcium citrate; re-evaluate PPI indication
Depo-Provera (DMPA) Medroxyprogesterone Hypothalamic suppression reduces endogenous estradiol Limit duration when possible; bone loss recovers upon cessation